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  Moristerole was orally administered in 20 cases of benign prostatic hypertrophy． One capsule
of MoristerolO contained 200 mg of soysterol． ln all the cases， 9 capsules of Moristerol＠ were given
per day in three divided doses for 6 weeks． Clinical improvement was observed in 11 of the 20 cases
（550／，）． lt consisted mal’nly of subjective complaints such as improvement of dysuria， narrow and
，366 泌尿紀要 29巻 3号 1983年
weak uriロary stream and feeling of inco皿plete voiding． As o句ective丘ndings， a statistically sig－
nificant decrease ofresidual urine volume was noted after treatment， although shrinkage of the enlarged
prostate was not clear upon palpation or roentgenography．
  In addition to the’improvemeht of syinpt’oms， s’eruin lipid perokide which might be considered
to be a provocative cause of benign prostatic hypertrophy， was alsg significantly decreasedby Moristerol＠
administration．
  No marked side effects were seen in this study．
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投与前      投与後
Fig．1．残尿量





















   投与前      投与後
Fig．4． トリグリセライドの変動
 4）副  作  用
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